Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Prudent Markets published a report for global HUMAN GROWTH HORMONE (HGH) market in this environment.
In terms of revenue, this research report indicated that the global HUMAN GROWTH HORMONE (HGH) market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of HUMAN GROWTH HORMONE (HGH) industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Eli Lilly and Company aims at producing XX HUMAN GROWTH HORMONE (HGH) in 2020, with XX % production to take place in global market, Ferring Holding SA accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of HUMAN GROWTH HORMONE (HGH) Market by Prudent Markets Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in HUMAN GROWTH HORMONE (HGH) Market
Eli Lilly and Company
Ferring Holding SA
Genentech
Merck & Co.
Novo Nordisk
Pfizer
Sandoz International GmbH
Ipsen
Novartis AG
Anhui Anke Biotechnology (Group) Co., Ltd
Biopartners GmbH
GeneScience Pharmaceuticals Co., Ltd
Lifetech Labs
Zhongshan Hygene Biopharm Co., Ltd
...
Major Type of HUMAN GROWTH HORMONE (HGH) Covered in Prudent Markets report:
Norditropin
Genotropin
Humatrope
Saizen
Omnitrope
Others
Application Segments Covered in Prudent Markets Market
Growth Hormone Deficiency
Turner Syndrome
Idiopathic Short Stature
Prader-Willi Syndrome
Small for Gestational Age
Others
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global HUMAN GROWTH HORMONE (HGH) Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 Norditropin -Product Introduction and Major Manufacturers
1.1.2 Genotropin -Product Introduction and Major Manufacturers
1.1.3 Humatrope -Product Introduction and Major Manufacturers
1.1.4 Saizen -Product Introduction and Major Manufacturers
1.1.5 Omnitrope -Product Introduction and Major Manufacturers
1.1.6 Others -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global HUMAN GROWTH HORMONE (HGH) Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)
2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)
3 Regional Market Analysis
3.1 China HUMAN GROWTH HORMONE (HGH) Market
3.1.1 Top Companies leading HUMAN GROWTH HORMONE (HGH) Development in China (2015-2020)
3.1.2 Sales Value of Major Company in China Market (2015-2020)
3.1.3 China HUMAN GROWTH HORMONE (HGH) Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2015-2026)
3.2 EU HUMAN GROWTH HORMONE (HGH) Market
3.2.1 Top Companies leading HUMAN GROWTH HORMONE (HGH) Development in EU (2015-2020)
3.2.2 Sales Value of Major Company in EU Market (2015-2020)
3.2.3 EU HUMAN GROWTH HORMONE (HGH) Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2015-2026)
3.3 USA HUMAN GROWTH HORMONE (HGH) Market
3.3.1 Top Companies leading HUMAN GROWTH HORMONE (HGH) Development in USA (2015-2020)
3.3.2 Sales Value of Major Company in USA Market (2015-2020)
3.3.3 USA HUMAN GROWTH HORMONE (HGH) Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2015-2026)
3.4 Japan HUMAN GROWTH HORMONE (HGH) Market
3.4.1 Top Companies leading HUMAN GROWTH HORMONE (HGH) Development in Japan (2015-2020)
3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
3.4.3 Japan HUMAN GROWTH HORMONE (HGH) Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2015-2026)
3.5 India HUMAN GROWTH HORMONE (HGH) Market
3.5.1 Top Companies leading HUMAN GROWTH HORMONE (HGH) Development in India (2015-2020)
3.5.2 Sales Value of Major Company in India Market (2015-2020)
3.5.3 India HUMAN GROWTH HORMONE (HGH) Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2015-2026)
3.6 Southeast Asia HUMAN GROWTH HORMONE (HGH) Market
3.6.1 Top Companies leading HUMAN GROWTH HORMONE (HGH) Development in Southeast Asia (2015-2020)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
3.6.3 Southeast Asia HUMAN GROWTH HORMONE (HGH) Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
3.7 South America HUMAN GROWTH HORMONE (HGH) Market
3.7.1 Top Companies leading HUMAN GROWTH HORMONE (HGH) Development in South America (2015-2020)
3.7.2 Sales Value of Major Company in South America Market (2015-2020)
3.7.3 South America HUMAN GROWTH HORMONE (HGH) Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2015-2026)
4 Value Chain (Impact of COVID-19)
4.1 HUMAN GROWTH HORMONE (HGH) Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on HUMAN GROWTH HORMONE (HGH) Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2026)
5.1 Global HUMAN GROWTH HORMONE (HGH) Sales and Growth Rate (2021-2026)
5.2 Global HUMAN GROWTH HORMONE (HGH) Sales Value and Growth Rate (2021-2026)
6 HUMAN GROWTH HORMONE (HGH) Competitive Analysis
6.1 Eli Lilly and Company
6.1.1 Eli Lilly and Company Company Profiles
6.1.2 Eli Lilly and Company Product Introduction
6.1.3 Eli Lilly and Company HUMAN GROWTH HORMONE (HGH) Production, Revenue (2015-2020)
6.1.4 SWOT Analysis
6.2 Ferring Holding SA
6.2.1 Ferring Holding SA Company Profiles
6.2.2 Ferring Holding SA Product Introduction
6.2.3 Ferring Holding SA HUMAN GROWTH HORMONE (HGH) Production, Revenue (2015-2020)
6.2.4 SWOT Analysis
6.3 Genentech
6.3.1 Genentech Company Profiles
6.3.2 Genentech Product Introduction
6.3.3 Genentech HUMAN GROWTH HORMONE (HGH) Production, Revenue (2015-2020)
6.3.4 SWOT Analysis
6.4 Merck & Co.
6.4.1 Merck & Co. Company Profiles
6.4.2 Merck & Co. Product Introduction
6.4.3 Merck & Co. HUMAN GROWTH HORMONE (HGH) Production, Revenue (2015-2020)
6.4.4 SWOT Analysis
6.5 Novo Nordisk
6.5.1 Novo Nordisk Company Profiles
6.5.2 Novo Nordisk Product Introduction
6.5.3 Novo Nordisk HUMAN GROWTH HORMONE (HGH) Production, Revenue (2015-2020)
6.5.4 SWOT Analysis
6.6 Pfizer
6.6.1 Pfizer Company Profiles
6.6.2 Pfizer Product Introduction
6.6.3 Pfizer HUMAN GROWTH HORMONE (HGH) Production, Revenue (2015-2020)
6.6.4 SWOT Analysis
6.7 Sandoz International GmbH
6.7.1 Sandoz International GmbH Company Profiles
6.7.2 Sandoz International GmbH Product Introduction
6.7.3 Sandoz International GmbH HUMAN GROWTH HORMONE (HGH) Production, Revenue (2015-2020)
6.7.4 SWOT Analysis
6.8 Ipsen
6.8.1 Ipsen Company Profiles
6.8.2 Ipsen Product Introduction
6.8.3 Ipsen HUMAN GROWTH HORMONE (HGH) Production, Revenue (2015-2020)
6.8.4 SWOT Analysis
6.9 Novartis AG
6.9.1 Novartis AG Company Profiles
6.9.2 Novartis AG Product Introduction
6.9.3 Novartis AG HUMAN GROWTH HORMONE (HGH) Production, Revenue (2015-2020)
6.9.4 SWOT Analysis
6.10 Anhui Anke Biotechnology (Group) Co., Ltd
6.10.1 Anhui Anke Biotechnology (Group) Co., Ltd Company Profiles
6.10.2 Anhui Anke Biotechnology (Group) Co., Ltd Product Introduction
6.10.3 Anhui Anke Biotechnology (Group) Co., Ltd HUMAN GROWTH HORMONE (HGH) Production, Revenue (2015-2020)
6.10.4 SWOT Analysis
6.11 Biopartners GmbH
6.12 GeneScience Pharmaceuticals Co., Ltd
6.13 Lifetech Labs
6.14 Zhongshan Hygene Biopharm Co., Ltd
7 Conclusion